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DNA Demethylation at Specific CpG Sites in the
IL1B Promoter in Response to Inflammatory Cytokines in
Human Articular Chondrocytes
Ko Hashimoto,1 Richard O. C. Oreffo,1 Marc B. Gibson,1 Mary B. Goldring,2
and Helmtrud I. Roach1
Objective. To determine whether changes in the
DNA methylation status in the promoter region of the
gene encoding interleukin-1 (IL-1) account for ex-
pression of IL1B messenger RNA (mRNA) after long-
term treatment of human articular chondrocytes with
inflammatory cytokines.
Methods. IL-1, tumor necrosis factor  (TNF)
plus oncostatin M (OSM), or 5-azadeoxycytidine (5-aza-
dC) was added twice weekly for 4–5 weeks to primary
cultures of normal human articular chondrocytes derived
from the femoral head cartilage of patients with a frac-
ture of the femoral neck. Expression of MMP13, IL1B,
TNFA, and DNMT1 was determined by SYBR Green–
based quantitative reverse transcription–polymerase
chain reaction (RT-PCR) analysis of genomic DNA and
total RNA extracted from the same sample before and
after culture. Bisulfite modification was used to identify
which CpG sites in the IL1B promoter showed differen-
tial methylation between IL1B-expressing and IL1B-
nonexpressing cells. The percentages of cells that were
methylated at that critical CpG site (–299 bp) were
quantified by a method that depended on methylation-
sensitive restriction enzymes and real-time RT-PCR.
Secretion of IL-1 into the culture media was assessed
by enzyme-linked immunosorbent assay.
Results. Healthy chondrocytes did not express
IL1B mRNA, but the levels were increased 5-fold by
treatment with 5-aza-dC and were increased 100–1,000-
fold by treatment with TNF/OSM. The percentage
CpG methylation was decreased by 5-aza-dC treatment
but was reduced considerably more by IL-1 and was
almost abolished by TNF/OSM. The mRNA was trans-
lated into protein in cytokine-treated chondrocytes.
Conclusion. These novel findings indicate that
inflammatory cytokines can change the DNA methyl-
ation status at key CpG sites, resulting in long-term
induction of IL1B in human articular chondrocytes.
Idiopathic osteoarthritis (OA) is a late-onset,
complex disease of the joint. It is characterized by
progressive failure of the extracellular cartilage matrix as
well as changes in the synovium and subchondral bone
(1,2). Susceptibility genes for OA, which represent po-
tential risks, have been indentified (3). However, the
disease probably develops following interactions with
the environment. Such interactions may be mediated by
epigenetically induced changes in gene expression that
are then transmitted to generations of daughter cells (4).
As in all adult somatic cells, the phenotype of
normal adult chondrocytes is stabilized by epigenetic
mechanisms, such as DNA methylation of CpG sites,
modifications of histone tails, and changes in chromatin
structure. DNA methylation is generally stable in so-
matic cells throughout adult life (5,6), whereas histone
modifications are readily reversible by specific enzymes
(7). During DNA replication, the methylation pattern is
rapidly reproduced on the nascent strand by DNA
methyltransferase 1 (DNMT-1), the maintenance DNA
methyltransferase (8,9). The histone code can be re-
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established after cell division by interactions of methyl
binding domains and DNMTs with histone methyltrans-
ferases and histone deacetylases (10,11). As a result,
both the DNA methylation pattern and the histone code
are reproduced during mitosis.
In normal adult articular cartilage, chondrocytes
synthesize cartilage matrix proteins, such as types II, IX,
and XI collagen as well as aggrecan. These molecules
impart tensile strength and compressive resistance to the
joint. Normally, chondrocytes maintain a low turnover of
cartilage matrix proteins, but in OA, many chondrocytes
undergo a phenotypic change and acquire a gene expres-
sion repertoire that is characterized by the aberrant
expression of numerous catabolic genes, including matrix
metalloproteinases (MMPs), aggrecanases (ADAMTS-4
and ADAMTS-5), inducible nitric oxide synthetase and
prostaglandins (12), interleukin-1 (IL-1) and other
cytokines (13,14), and many more genes (15,16). This
change in gene expression does not take place in all OA
chondrocytes, but predominantly in chondrocytes of the
surface zone and near weight-bearing regions (17). To
distinguish these chondrocytes from OA chondrocytes
with a normal gene expression repertoire, they will be
referred to as “degradative” chondrocytes. Disease pro-
gression correlates with an increase in the number of
these degradative chondrocytes.
Gene expression is regulated by both epigenetic
and nonepigenetic mechanisms. Genes that are part of
the repertoire of a particular cell type show DNA hypo-
methylation, and chromatin has an open structure. This
permits the binding of specific transcription factors in
combination with cofactors (e.g., histone acetylases and
methylases) that mediate rapid responses (minutes to
hours) to inductive or repressive factors. Genes that are
not part of a given repertoire tend to be permanently
silenced by DNA hypermethylation; this prevents access
of the relevant transcription factors to their promoter.
Epigenetic silencing is essential to insure genomic sta-
bility throughout life.
Epigenetic disruption may activate normally si-
lent genes (18), or it may silence normally expressed
genes. This is precisely the situation in degradative OA
chondrocytes, where many nonchondrocytic genes are
permanently activated. So far, only a few studies have
dealt with the question of whether the aberrant gene
expression in OA is linked to loss of DNA methylation.
Our group (19,20) has previously demonstrated hypo-
methylation at specific CpG sites in the promoters of
MMP-3, MMP-9, MMP-13, and ADAMTS-4 in degra-
dative OA chondrocytes. Iliopoulos et al (21) have
shown that the aberrant induction of leptin in OA is
associated with loss of DNA methylation. On the other
hand, loss of osteogenic protein 1 (OP-1) expression in
aged chondrocytes is correlated with hypermethylation
of the OP-1 promoter (22).
Because of the association of aberrant expression
of proteases with DNA demethylation, it is of interest to
identify factors that cause a loss of DNA methylation.
The aberrant expression of nonchondrocytic genes that
occurs in OA can, to some extent, be reproduced in vitro
by treating healthy chondrocytes with either IL-1 (23)
or tumor necrosis factor  (TNF), especially in combi-
nation with oncostatin M (OSM) (24). However, it is not
known whether this aberrant induction depends solely
on nonepigenetic regulation by transcription factors or
whether epigenetic changes are also involved. In the first
case, one would expect expression to be induced within
hours and be readily reversible by cytokine withdrawal.
In the second case, induction might take days or weeks,
but expression would probably persist after cytokine
withdrawal.
We hypothesized that the latter situation is linked
to demethylation of specific CpG sites in the relevant
promoter regions, whereas this is not the case for
short-term induction. To test our hypothesis, messenger
RNA (mRNA) expression of IL1B, an aberrantly in-
duced gene, was compared with the DNA methylation
status in primary human chondrocytes cultured in the
presence and absence of inflammatory cytokines.
PATIENTS AND METHODS
Chondrocyte isolation. Human articular cartilage was
obtained after hemiarthroplasty following femoral neck frac-
ture or following total hip arthroplasty for OA. Cartilage was
dissected from femoral heads within 6 hours of surgery. In
total, tissues from 21 patients with femoral neck fracture and
12 patients with OA were used in this study. Permission of the
Local Ethics Committee and the consent of the patients were
obtained prior to the study.
A previous study (25) showed that the deep zones of
cartilage from patients with femoral neck fracture contained
healthy, albeit aged, chondrocytes that did not aberrantly
express proteases and cytokines. However, the superficial zone
contained a few cells with aberrant expression. This zone
typically displayed a pinkish coloring, so that it was relatively
easy to separate this zone from the deep zone with a scalpel. In
the OA patients, a significant amount of cartilage had already
been degraded, especially at the weight-bearing regions. To
obtain enough cartilage, we collected the “surface zone” car-
tilage irrespective of whether this was actually the superficial,
intermediate, or deep zone. It was possible to obtain proper
deep-zone OA cartilage only if thick cartilage had remained at
non–weight-bearing regions, which was not always the case.
To liberate the cells, cartilage pieces were cut into
small fragments and digested with 10% trypsin (Lonza, Wok-
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ingham, UK) in phosphate buffered saline (PBS) for 30
minutes, in 1 mg/ml of hyaluronidase (Sigma-Aldrich, Gilling-
ham, UK) in PBS for 15 minutes, and in 10 mg/ml of
collagenase B (Roche, Lewes, UK) in -modified Eagle’s
medium (-MEM; Sigma-Aldrich, Gillingham, UK) for 12–
15 hours at 37°C.
Chondrocyte culture. For culture, we used only
non-OA chondrocytes from the deep zone of tissues from
patients with femoral neck fracture (25). Before treatment,
chondrocytes were cultured for 48 hours at a density of 2–4 
105 cells/25-cm2 flask in 5 ml of -MEM supplemented with
10% fetal calf serum (FCS; Invitrogen, Paisley, UK), 1%
insulin–transferrin–selenium (Sigma-Aldrich), 100 units/ml of
penicillin and 100 g/ml of streptomycin (Lonza), and
100 g/ml of ascorbic acid (Sigma-Aldrich) in an atmosphere
of 5% CO2 at a temperature of 37°C. In the first experiment,
chondrocytes were cultured until confluence, passaged once,
incubated with a single addition of 10 ng/ml of IL-1 plus 10
ng/ml of OSM, and harvested after 24 or 72 hours. Other
passage 1 cultures were treated with cytokines at each change
of medium for a total of 3 weeks. Half of the cultures were then
harvested by trypsinization, whereas the other half was pas-
saged again and cultured without cytokine treatment until
confluence at 2 weeks.
In another experiment, chondrocytes were divided into
5 groups immediately after isolation: noncultured, cultured
without treatment (control culture), cultured with 2 M
5-azadeoxycytidine (5-aza-dC), cultured with 10 ng/ml of IL-
1, and cultured with a mixture of 10 ng/ml of TNF plus
10 ng/ml of OSM. For the group cultured with 5-aza-dC, the
histone deacetylase inhibitor trichostatin A (300 nM) was
added just once, at the first treatment, to facilitate access of
5-aza-dC, a cytidine analog that inhibits the activity of
DNMT-1 (26). This results in the nonspecific loss of DNA
methylation during cell division. The media were changed
twice each week, when reagents were also added. These
primary cultures were maintained for 4–5 weeks until they
reached confluence.
DNA and RNA extraction. Genomic DNA and total
RNA were extracted simultaneously from the harvested chon-
drocytes with the use of an AllPrep DNA/RNA Mini kit
(Qiagen, Crawley, UK) according to the manufacturer’s in-
structions. RNA was immediately reverse-transcribed with
avian myeloblastosis virus reverse transcriptase and both
oligo(dT)15 and random primers (27).
Quantitative reverse transcription–polymerase chain
reaction (RT-PCR). Relative quantification of gene expression
was performed with an ABI Prism 7500 detection system
(Applied Biosystems, Warrington, UK). Reactions were per-
formed in triplicate, with GAPDH as the internal control.
Primer Express 3.0 software (Applied Biosystems) was used to
design primers across exon–exon boundaries. The primers for
IL1B were commercially designed by PrimerDesign
(Southampton, UK), and the sequence for COL2A1 was taken
from reference 28. Messenger RNA expression was quantified
according to the 2Ct method. The 25-l reaction mixture
we used contained 1 l of complementary DNA, 12.5 l of 2
Power SYBR Green PCR Master Mix, and 500 M of each
primer. Thermocycler conditions consisted of an initial activa-
tion step at 95°C for 10 minutes, followed by a 2-step PCR
Figure 1. CpG methylation map for the proximal IL1B promoter. Normal chondrocytes were isolated
from 4 patients with femoral neck fracture and cultured for 4–5 weeks with or without interleukin-1
(IL-1) or tumor necrosis factor  (TNF)/oncostatin M (OSM). Methylation status was determined by
bisulfite modification. Each circle represents the average result of 6 sequenced clones. The CpG site at
299 bp was selected for quantification.
DNA DEMETHYLATION OF IL1B IN RESPONSE TO INFLAMMATORY CYTOKINES 3305
program of 95°C for 15 seconds and 60°C for 60 seconds for 40
cycles. A dissociation curve was obtained for each quantitative
PCR run.
Bisulfite modification. Genomic DNA was modified
with MethylDetector (Active Motif, Rixensart, Belgium), ac-
cording to the manufacturer’s instructions. The MethPrimer
website (http://www.urogene.org/methprimer) was used to de-
sign primers that contained no CpG sites. Twenty-one CpG
sites located between 1,300 and 15 bp were investigated
with 3 pairs of nested PCR primers (Figure 1). The sequences
of all primers we used can be found at http://www.som.
soton.ac.uk/research/dohad/groups/bone/Supplementary.asp.
Thermocycler conditions comprised an activation step
at 94°C for 2 minutes, followed by a 3-step PCR program,
which consisted of 94°C for 30 seconds, 55°C for 60 seconds,
72°C for 60 seconds for 35 cycles, and a final extension at 72°C
for 3 minutes. The PCR products were diluted 50, and inner
reactions were run. The PCR products were cloned with the
TOPO TA Cloning kit using One Shot TOP 10 Chemically
Competent Escherichia coli (Invitrogen, Paisley, UK), followed
by purification of the plasmids with a PureLink Quick Plasmid
MiniPrep kit (Invitrogen). Six plasmids were sequenced for each
sample by Eurofins MWG Operon (Ebersberg, Germany).
Determining the percentage methylation at299 bp in
the IL1B promoter. The CpG site at 299 bp in the IL1B
promoter was selected for quantification because it was differ-
entially methylated in control versus cytokine-treated cultured
cells (Figure 1) and because it is recognized by a methylation-
sensitive restriction enzyme, namely, Hpy CH4IV (New En-
gland BioLabs, Frankfurt, Germany). Fully methylated DNA
and fully nonmethylated DNA were used to estimate nonspe-
cific digestion and incomplete digestion, respectively, as well as
to generate a standard curve. CpGenome Universal Methyl-
ated DNA was obtained from Millipore (Eastleigh, UK), and
fully nonmethylated DNA was generated from the fully meth-
ylated DNA by whole-genome amplification with an Illustra
GenomiPhi V2 DNA Amplification kit (GE Healthcare Life
Sciences, Little Chalfont, UK).
DNA concentrations were measured using a Nano-
Drop instrument (Thermo Scientific, Welwyn Garden City,
UK) and were adjusted to 4 ng/l (20 ng of DNA in 5 l).
Hpy CH4IV was diluted to contain 2 units/2.5 l of enzyme
solution. These concentrations had previously been deter-
mined as optimal (27). Each digestion sample consisted of a
final volume of 8.3 l, containing 5 l of diluted DNA, 2.5 l
of diluted Hpy CH4IV, and 0.8 l of 10 NE Buffer I. All
prepared samples, together with controls, were incubated at
37°C for 12 hours, followed by heat inactivation at 65°C for
20 minutes.
PCR for the percentage methylation analysis was per-
formed as for the RT-PCR analysis. Each run included no-
enzyme controls, fully methylated and nonmethylated DNA
controls, the standard curve, and the enzyme-treated DNA
samples. The DNA content of each enzyme-digested sample
was normalized to its corresponding no-enzyme control, and
the percentage methylation was calculated from the standard
curve (27).
When articular cartilage from the femoral neck frac-
ture samples were compared with articular cartilage from the
OA samples for mRNA expression or for the percentage of
DNA methylation, all samples were analyzed in the same assay.
Enzyme-linked immunosorbent assay (ELISA) for
IL-1 in culture media. At the end of culture, the media con-
taining the cytokines were removed, and after thorough wash-
Figure 2. Differential expression of A, IL1B and B, TNFA, as determined by quantitative reverse transcription–polymerase chain reaction analysis.
Articular cartilage was obtained from patients with femoral neck fracture (#NOF) or from patients with osteoarthritis (OA). Surface zones of the
cartilage were removed and analyzed separately from the deep zones. Results are shown for individual patients, arranged in order of age. For each
gene, femoral neck fracture and OA samples were analyzed in the same assay. The low levels of IL1B expression in the surface zone of cartilage
from femoral neck fracture patients contrast with the 100–1,000-fold increased expression in the surface zone of cartilage from OA patients. With
1 exception (a 72-year-old man), expression increased with age in the OA samples. There was no expression of IL1B in the deep zones of cartilage
from the femoral neck fracture patients (1 exception, a 76-year-old woman) or the OA patients. In contrast, TNFA was expressed in the control
chondrocytes located in the deep zone of cartilage from femoral neck fracture patients and expression did not increase significantly in chondrocytes
from the surface layer of cartilage from OA patients. Values are the mean and SD.
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ings to remove any remaining exogenous IL-1, 5 ml of fresh
medium with 1% FCS was added. After 48 hours, the media
were harvested and stored at 80°C until analysis with the
human IL-1/IL-1F2 Quantikine ELISA kit (R&D Systems,
Abingdon, UK).
Statistical analysis. The data for IL-1 expression and
percentage methylation were analyzed in Microsoft Excel
(Microsoft, Redmond, WA) using Wilcoxon’s signed rank test.
P values less than 0.05 were considered significant. Other data
are expressed as the mean  SD.
RESULTS
Identifying differentially methylated CpG sites.
Of the 20 CpG sites in the 1,300-bp sequence upstream
of exon 1 (Figure 1), 16 were methylated in all cultures.
This suggests that epigenetic regulation does not involve
the region between 1,300 and –583 bp. The Ava I site
at 511 bp and the 2 CpG sites that encompass the
transcription start site (20 and 13) were essentially
nonmethylated in all groups. In contrast, the 2 CpG sites
at299 and256 bp were methylated in control samples,
but had become demethylated in cytokine-treated chon-
drocytes. Because only the site at 299 bp was cleavable
by a methylation-sensitive restriction enzyme, this site
was selected for quantitative analysis in subsequent
experiments.
Differential expression of IL1B, but not TNFA, in
control and OA cartilage. To investigate the zonal
distribution of IL1B-expressing chondrocytes in vivo,
mRNA expression in the superficial and deep zones of
OA and control cartilage was assessed separately. Ex-
pression was 10–1,000-fold higher in the surface layer of
OA cartilage as compared with femoral neck fracture
cartilage (Figure 2A). The variability among patients
bore some relationship to age, in that, with 1 exception,
expression increased markedly with age. In contrast to
Figure 3. Effects of cytokine withdrawal following short-term (A–C) or long-term (D–F)
treatment with interleukin-1 (IL-1)/oncostatin M (OSM) on expression of the indicated
genes. A–C, The catabolic genes MMP13 and IL1B were up-regulated several hundredfold
at 24 hours following the addition of a single dose of IL-1/OSM, whereas COL2A1 was
down-regulated. After 72 hours with no further cytokine treatment, expression of the
catabolic genes was down-regulated again to near-normal levels, but expression of COL2A1
was not regained. D–F, When IL-1/OSM was added twice a week for 3 weeks to passage
1 cells (P1 IL-1), the catabolic genes MMP13 and IL1B were again considerably
up-regulated. Cells were then passaged and cultured for a further 3 weeks during which no
cytokines were added (P2 no IL-1). This time, expression was maintained even in the
absence of cytokines, a finding consistent with the permanent induction of gene expression.
COL2A1 expression was abolished by the cytokines, and the levels remained low throughout
the experiment. Results are representative of 4 experiments. Values are the mean and SD.
Numbers at the top of the bars are the values that are represented by the bars.
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the findings in the superficial zone, no expression of
IL1B was apparent in the deep zone of OA cartilage. In
the femoral neck fracture samples, very low expression
was found in the surface layer, but not in the deep zone.
These findings confirm that the deep zone of
cartilage from patients with femoral neck fracture con-
tains chondrocytes that do not express IL1B and are
therefore suitable for culture experiments. A previous
study of ADAMTS-4 expression showed similar differ-
ential expression (20). In contrast to IL1B, TNFA ex-
pression was not significantly different in the surface and
deep zones (Figure 2B); this supports the notion that
IL-1, but not TNF, is the major cytokine involved in
the pathology of OA.
Persistent aberrant expression of MMP3,
MMP13, and IL1B with long-term cytokine treatment. A
single treatment with IL-1/OSM induced the aberrant
expression of MMP3 (data not shown), MMP13 (Figure
3A), and IL1B (Figure 3B) within 24 hours (Figure 3A).
By 72 hours, enzyme expression had declined or disap-
peared. In contrast, when expression was induced by the
repeated addition of IL-1/OSM during 3 weeks of
incubation, the expression persisted for 3 more weeks
without further cytokine treatment (Figures 3D and E).
COL2A1 expression was reduced after a single addition
of cytokine and remained low throughout the experi-
ments (Figures 2C and F)
Increased expression of IL1B following experi-
mental demethylation. If DNA demethylation underpins
aberrant IL1B expression in chondrocytes, then experi-
mentally induced demethylation should result in in-
creased expression. When normal chondrocytes were
cultured with 5-aza-dC, the expression of IL1B increased
3.6–8.6-fold (mean  SD 5.5  2.2–fold increase) com-
pared with control cultures (Figure 4A). To check that
5-aza-dC treatment had actually resulted in loss of DNA
methylation in the IL1B promoter, we quantified the
percentage of methylation. As shown in Figure 4B, a
mean  SD of 61.0  6.1% of the chondrocytes were
methylated in uncultured chondrocytes. In cultured sam-
ples, this value was reduced to 44.8  9.9%, indicating
that culture per se could cause a limited loss of DNA
methylation. However, 5-aza-dC further reduced the
percentage of DNA methylation to 33.6  5.7%. The
results showed that the experimentally induced loss of
DNA methylation results in increased gene transcrip-
tion, thus confirming a cause-and-effect relationship
between DNA demethylation and transcription.
Increased expression of IL1B (100–1,000-fold)
with long-term exposure to cytokines. Healthy chondro-
cytes were cultured for 4–5 weeks with twice-weekly
Figure 4. DNA demethylation and aberrant gene expression follow-
ing long-term treatment with cytokines. Chondrocytes were cultured
with 5-azadeoxycytidine (5-aza-dC) (A and B) or with interleukin-1
(IL-1) or tumor necrosis factor  (TNF)/oncostatin M (OSM)
(C–F), and the relative expression of mRNA for IL1B was compared
with the percentage of DNA methylation at 299 bp in the IL1B
promoter. A and B, Culture itself induced some IL1B expression (A)
and a 20% loss in DNA methylation (B). Addition of 5-aza-dC
increased the expression 5-fold as compared with control culture and
caused a further loss of DNA methylation. Values are the mean and
SD of 6 samples.   P  0.05. C and D, Relative expression of IL1B
(C) and percentage of DNA methylation (D) in chondrocytes from 6
individual patients (patient numbers shown across the x-axis). Chon-
drocytes were not cultured, were cultured alone, or were cultured with
IL-1 or TNF/OSM. No IL1B was detected in noncultured chondro-
cytes. Culture itself induced low expression (set at 1), but culture with
IL-1 or TNF/OSM considerably increased IL1B expression. Before
culture, 60% of cells were methylated. Culture alone reduced DNA
methylation, which was significant in patients 406 and 421. However,
cytokine treatment caused a greater loss of DNA methylation, partic-
ularly the combined treatment with TNF/OSM. Values are the mean
and SD of 6 individual samples. Numbers at the top of the bars are the
values that are represented by the bars. E and F, Overall mean and SD
values for the relative expression of IL1B (E) and the percentage of DNA
methylation (F) in the 6 individual samples shown in C and D, respec-
tively. The differences between all groups were significant at P  0.05.
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additions of either IL-1 or TNF/OSM (Figure 4C).
The absence of expression in noncultured chondrocytes
was confirmed, and the low expression induced by
culture alone was set at 1. Treatment with IL-1 in-
creased the expression of IL1B 16–197-fold, while the
combination of TNF/OSM increased expression of
IL1B by 306–1,748-fold compared with control cultures
(P  0.01). This showed that the capacity of the cyto-
kines to increase expression was several orders of mag-
nitude greater than that of 5-aza-dC.
Loss of DNA methylation with long-term expo-
sure to cytokines. Quantitative analysis showed that
culture alone reduced DNA methylation in cartilage
samples from 2 patients (patients 406 and 421), but this
decrease was not significant as compared with the other
patients. In contrast, the effects of the cytokines were
very prominent. Only 4–25% (mean  SD 17.9  6.9%)
of the IL-1–treated chondrocytes were still methylated
at –299 bp, and with the combined TNF/OSM treat-
ment, only 0–8% (mean  SD 4.5  3.7%) of the cells
remained methylated. Although there was no direct
linear correlation between the fold increases in gene
expression and the loss of DNA methylation, the trends
are very clear: samples with the greatest loss of DNA
methylation showed, on the whole, the greatest induc-
tion of gene transcription.
Association of increased IL1B expression with
the release of IL-1 protein into the medium. Significant
amounts of IL-1 protein were produced by chondro-
cytes that had been cultured with either IL-1 or TNF/
OSM, but no IL-1 was detected in control cultures or in
cultures treated with 5-aza-dC. This indicates that the
small increases in transcription induced by 5-aza-dC did
not produce measurable amounts of IL-1 protein.
Treatment with exogenous IL-1 resulted in the release
of 0.011–0.225 pg of IL-1 per g of DNA per hour,
while TNF/OSM treatment caused the release of
0.066–0.169 pg of IL-1 per g of DNA per hour. These
findings indicate that the increased expression of IL1B,
a likely result of transcriptional promoter activation,
resulted in increased synthesis of IL-1 protein.
No increase in TNFA expression by chondrocytes
following treatment with cytokine. Because IL-1 in-
duced its own expression in vitro, we explored whether
the same was true for TNF. Noncultured chondrocytes
expressed TNFA (Figure 2B), and culture of chondro-
cytes had no further effect. The expression of TNFA in
chondrocyte cultures treated with IL-1 or TNF/OSM
was not significantly different from that in the cultured
controls, with a mean  SD increase in expression of
0.59  0.44–fold and 0.91  0.49–fold, respectively.
Thus, in contrast to the expression of IL1B, treatment
with inflammatory cytokines did not increase TNFA
expression in vitro.
Decreased DNMT1 expression following culture
and cytokine treatment. To determine whether de-
creased expression of DNMT1 contributed to the ob-
served loss of DNA methylation, we used quantitative
RT-PCR to investigate its expression. Indeed, DNMT1
expression in OA chondrocytes from the surface zone
was half that in control chondrocytes from patients with
femoral neck fracture (Figure 5A). Culture alone also
reduced DNMT1 expression to around half that in
noncultured chondrocytes, which may partly explain the
loss of DNA methylation in control cultures. Addition of
IL-1 or TNF/OSM caused only a small further de-
crease compared with control (Figure 5B).
DISCUSSION
The novel findings of the present study are that
inflammatory cytokines have the capacity not only to
induce changes in gene expression, but also to demeth-
ylate specific CpG sites in the proximal IL1B promoter.
IL-1 is at the apex of several inflammatory cascades
and is one of the most important cytokines in OA,
although the debate is ongoing.
Because IL-1 has a very short half-life and the
mRNA transcript levels correspond to the protein levels,
it is important to understand transcriptional regulation
of this protein. Nonepigenetic regulation of the IL1B
Figure 5. Expression of DNMT1 in articular chondrocytes in vivo (A)
and in vitro (B). DNMT1 expression in articular cartilage chondro-
cytes from patients with osteoarthritis (OA; n  5) was less than half
that in control chondrocytes from patients with femoral neck fracture
(#NOF; n  5) (P  0.05). In vitro, culture alone had the greatest
effect (P  0.01), and the decreased expression in control chondro-
cytes from patients with femoral neck fracture was of similar magni-
tude to that in chondrocytes from patients with OA. In addition,
treatment with tumor necrosis factor (TNF)/oncostatin M (OSM)
further decreased expression compared with noncultured cells (P 
0.01). Values are the mean and SD of chondrocyte cultures from 6
patients.
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promoter has been studied extensively in monocyte/
macrophages. In these cells, IL1B is readily induced by a
variety of stimuli, including IL-1 itself (29,30). The
CpG region between 131 and 12 bp is sufficient to
direct the expression of a reporter gene (31), but an
inducible enhancer located between 3,134 and 2,729
bp (31,32) is also involved in signal-dependent expres-
sion. In monocytes, this promoter is packaged into a
nontranscribed, but “poised,” promoter structure that is
characterized by a histone-free transcription start site
and constitutive association with the transcription fac-
tors PU.1 and CCAAT/enhancer binding protein 
(c/EBP) (30). Monocytes are thus primed for rapid
activation in response to pathologic or other stimuli.
Articular chondrocytes do not normally express
IL1B, as confirmed here by quantitative RT-PCR. The
low level of expression observed in the superficial zone
of articular cartilage from patients with femoral neck
fracture probably indicates an age-related change to
“degradative” chondrocytes in a few cells. In contrast,
the chondrocytes located near the surface of OA carti-
lage showed very high levels of IL1B expression, whereas
this was undetectable in deep-zone OA cartilage. We
hypothesized that IL1B was silenced by DNA methyl-
ation in normal chondrocytes and that demethylation
had occurred in OA, as previously reported for MMPs
and ADAMTS-4 (19).
To investigate the epigenetic regulation of IL1B,
we studied the proximal promoter because its activity
regulates cell-type–specific expression (33). When the
CpG locations were compared with the transcription
factor binding sites (Figure 6), the latter were concen-
trated in 2 CpG-free regions, each bracketed by CpG
sites. Interestingly, the site at 511 bp and the 2 CpG
sites around the transcription start site (20 and 13
bp) were unmethylated, whether IL1B was expressed or
not. The 2 CpG sites that were differentially methylated
and where the methylation status was inversely corre-
lated with expression (256 and 299 bp) were located
between the 2 regions that contain multiple transcription
factor binding sites and bracketed an NF-B binding
site. Both IL-1 and TNF activate NF-B (34–36),
which in turn, activates many genes (37), including IL1B
and other catabolic genes induced in OA. Perhaps more
relevant in the present context is the fact that NF-B
may be involved in demethylation (38), although the
details are not clear. The observation (39) that in
intestinal inflammation, TNF-induced NF-B expres-
sion was associated with demethylation of CpG islands
supports the inference that NF-B may play a role in
demethylation in the experiments described herein.
Having identified the differentially methylated
CpG sites, we determined the percentage of cells that
were methylated at 299 bp (27). Even in control
chondrocytes, which do not express IL1B, the percent-
age methylation was only 60%, rather than the ex-
pected 100%. This raises the question of why 40% of the
nonmethylated cells did not express IL1B. Hypomethy-
lation is a necessary, but not sufficient, condition for
gene activation, inasmuch as histone modifications are
also required. Deacetylated histones or methylated his-
tone H3 lysine 9 (H3K9) and H3K27 can, in theory,
silence a gene even in the absence of DNA methylation.
An alternative possibility is that normal articular chon-
drocytes do not contain the transcription factors re-
quired for IL1B expression.
Thus, the rapid induction after 24 hours could
depend on cytokine-induced histone modifications
and/or activation of transcription factors in cells with
preexisting demethylation. In support of this notion,
Figure 6. Proximal promoter of IL1B. Vertical bars indicate the positions of CpG sites. The CpG
sites at 299 and 256 bp bracket an NF-B binding site.
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IL-1 has been shown to translocate to the nucleus and
to interact with histone acetyltransferase in yeast strains
(40). Whether this also applies to IL-1 is not known.
Up-regulation of IL1B after short-term treatment did
not persist, yet after long-term treatment, the expression
of IL1B persisted for at least 2 weeks after the inducer
had been withdrawn. This is consistent with permanent
epigenetic changes. Because the pathology of OA in-
volves long-term aberrant induction of IL-1 and pro-
teases, short-term in vitro experiments are unlikely to
model the situation in vivo.
Further evidence of a cause-and-effect relation-
ship between DNA methylation and gene expression was
obtained in 5-aza-dC–treated cultures, in which the
experimentally induced loss of DNA methylation in-
creased the expression of IL1B by 5-fold. Treatment
with 5-aza-dC reduced, yet did not abolish, the percent-
age of methylation. One reason may be that 5-aza-dC,
whose half-life is 4 hours (26), can act only on those
cells that undergo cell division during that time. Because
5-aza-dC was added 3 times per week, it is likely that
active 5-aza-dC was not present at all times when cell
division took place.
Treatment with cytokines, rather than with 5-aza-
dC, was much more effective at inducing gene expres-
sion. This was especially true for the combination of the
2 cytokines (TNF/OSM). TNF with or without OSM
has frequently been used to induce the expression of
degradative proteases in cultured chondrocytes (34,41).
The findings presented here show that the TNF/OSM
combination is also highly effective in stimulating IL1B
in chondrocytes, increasing its expression up to 1,000-
fold. OSM belongs to the IL-6 family, acts via JAK/
STAT signaling, and can, on its own, induce cartilage
degradation in vitro (42), but it is usually used together
with TNF (43) or IL-1 (24,41) to enhance the cyto-
kine effect. The percentage of DNA methylation corre-
lated negatively with increases in IL1B expression, al-
though this varied considerably among patients. Samples
treated with TNF/OSM had the highest expression
level and the greatest loss of DNA methylation. Indeed,
DNA methylation was completely abolished in some
samples.
Based on these findings, it is evident that long-
term aberrant expression of IL1B was a consequence of
DNA demethylation, presumably caused by inflamma-
tory cytokines. The question then arises of how cyto-
kines can achieve greater DNA demethylation than
5-aza-dC. Because 5-aza-dC inhibits DNMT1, we sought
to determine whether cytokines also alter DNMT1 ex-
pression. This was indeed reduced in vitro by the cyto-
kines and in OA chondrocytes as compared with femoral
neck fracture control chondrocytes in vivo. However,
since culture per se significantly reduced expression,
lower expression of DNMT1 alone could not explain the
results. We hypothesize that activation of NF-B plays a
major role in cytokine-induced DNA demethylation
(38), but further studies are required.
There are several caveats that should be borne in
mind. When chondrocytes are grown in monolayer for
several weeks, their phenotype is lost. However, explants
of articular cartilage in organ culture, in which the
chondrocyte phenotype is maintained, exhibit little or no
loss of DNA methylation or gene induction. This sug-
gests that the extracellular matrix protects the cells from
loss of phenotype and possibly from loss of DNA
methylation. To maintain genomic stability in vivo, one
would expect resistance to changes in DNA methylation
status in healthy, fully differentiated cells, and the
extracellular matrix might provide increased resistance
in explant cultures. Monolayer cultures probably sensi-
tize chondrocytes to epigenetic changes, so that one can
obtain within weeks the phenotype changes that proba-
bly take years to occur in OA. The extent to which the
protease-producing “degradative” cells are still chondro-
cytes is a matter for debate.
One should also be careful about extending these
in vitro findings to the in vivo situation. In vitro,
decreased expression of COL2A1 was observed after a
single addition of cytokine, whereas in vivo, increased
COL2A1 expression was observed in surface-zone OA
chondrocytes as compared with femoral neck fracture
chondrocytes (data not shown), suggesting that the
cultures do not model the vivo situation as far as
COL2A1 is concerned. There is also some disagreement
about the importance of IL-1 in OA. We have observed
significant expression of IL1B in chondrocytes of the
superficial zone of OA cartilage, where cytokines have
also been immunolocalized (44,45). In contrast, Fan et al
(46) found no significant up-regulation of IL1B in OA
patients, but those investigators had used early degen-
erated cartilage from the knee joint, with the deep zone
included. In IL-1–knockout mice, experimentally in-
duced OA was either enhanced or reduced (47,48),
depending on genetic background, whereas overexpres-
sion of human TNF induced severe inflammatory
arthritis (49). However, the mouse models may not be
representative of human OA.
In summary, our novel findings support the con-
clusion that the long-term cytokine-stimulated induction
of IL1B in human articular chondrocytes in vitro in-
volves the loss of DNA methylation. If applicable in vivo,
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then the mechanisms for OA progression may involve
the following. An initial episode of inflammation in the
synovium, perhaps as a consequence of mechanical
stress, activates synovial macrophages to produce IL-1
and TNF. These cytokines diffuse into the articular
cartilage. There, the cytokines induce aberrant expres-
sion of proteases and IL1B in the chondrocytes (50). If
this induction leads to the loss of DNA methylation,
IL1B will now be included in the expression repertoire
of the OA chondrocytes, even after the synovial inflam-
mation has abated. This scenario may explain why
protease inhibitors, such as tissue inhibitors of metallo-
proteinases, have little effect when injected into the joint
and why, once degradative processes have been opera-
tive, OA progression cannot be halted.
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